Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle

被引:0
作者
Brin, Mitchell F. [1 ,2 ]
Winner, Paul [3 ]
Blumenfeld, Andrew M. [4 ]
Eross, Eric J. [5 ]
Orejudos, Amelia [1 ]
Adams, Aubrey Manack [1 ]
机构
[1] Allergan Plc, Irvine, CA USA
[2] Univ Calif Irvine, Irvine, CA USA
[3] Premiere Res Inst Palm Beach Neurol, Palm Beach Headache Ctr, W Palm Beach, FL USA
[4] Headache Ctr Southern Calif, Neurol Ctr, Carslbad, CA USA
[5] CORE Inst, Scottsdale, AZ USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
P4.123
引用
收藏
页数:3
相关论文
共 50 条
[41]   Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study [J].
Rothrock, John F. ;
Luo, Lei ;
Eross, Eric ;
Sommer, Katherine ;
Blumenfeld, Andrew M. .
NEUROLOGY, 2020, 94 (15)
[42]   Descriptive comparison of the efficacy and safety of onabotulinumtoxina for headache prophylaxis in adult chronic migraine patients from two long-term, multicenter studies: compel vs. Preempt [J].
Aurora, S. ;
Stark, R. ;
Reppine, A. ;
Adams, A. Manack ;
Blumenfeld, A. .
CEPHALALGIA, 2015, 35 :47-47
[43]   Safety and tolerability of long-term albumin treatment in patients with decompensated cirrhosis [J].
Fernandez, Javier ;
Nunez, Laura ;
Costa, Montserrat ;
Torres, Mireia ;
Horrillo, Raquel ;
Afonso, Natalia ;
Mestre, Anna ;
Del Arbol, Luis Ruiz ;
Villanueva, Candid ;
Paez, Antonio ;
Arroyo, Vicente .
JOURNAL OF HEPATOLOGY, 2024, 80 :S231-S231
[44]   Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study [J].
Rothrock, J. F. ;
Luo, L. ;
Eross, E. J. ;
Sommer, K. ;
Blumenfeld, A. M. .
HEADACHE, 2020, 60 :93-93
[45]   Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study [J].
Young, William B. ;
Lopez, J. Ivan ;
Rothrock, John F. ;
Orejudos, Amelia ;
Adams, Aubrey Manack ;
Lipton, Richard B. ;
Blumenfeld, Andrew M. .
JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1)
[46]   OnabotulinumtoxinA for the Treatment of Chronic Migraine [J].
Rothrock, John F. .
HEADACHE, 2011, 51 (04) :659-660
[47]   Descriptive Comparison of the Efficacy and Safety of OnabotulinumtoxinA for Headache Prophylaxis in Adult Chronic Migraine Patients from Two Long-term, Multicenter Studies: COMPEL vs. PREEMPT [J].
Aurora, S. ;
Stark, R. ;
Reppine, A. ;
Adams, Manack A. ;
Blumenfeld, A. .
HEADACHE, 2015, 55 :142-142
[48]   Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study [J].
William B. Young ;
J. Ivan Lopez ;
John F. Rothrock ;
Amelia Orejudos ;
Aubrey Manack Adams ;
Richard B. Lipton ;
Andrew M. Blumenfeld .
The Journal of Headache and Pain, 2019, 20
[49]   OnabotulinumtoxinA for Treatment of Chronic Migraine [J].
Markert, Ronald J. ;
Solomon, Glen D. .
HEADACHE, 2011, 51 (06) :1002-1003
[50]   Eighteen-month long-term analysis of the effectiveness, safety and tolerability of subcutaneous sumatriptan in acute migraine treatment [J].
Gobel, H ;
Stolze, H ;
Heinze, A ;
Dworschak, M ;
Heuss, D ;
Christiani, K ;
Lindner, V .
NERVENARZT, 1996, 67 (06) :471-483